San Francisco, United States
Atomwise, founded in 2012, is at the forefront of transforming drug discovery through artificial intelligence. The company's slogan, "Better Medicines Faster", encapsulates its mission to expedite pharmaceutical innovations. Specializing in preclinical drug development, Atomwise has distinguished itself by pioneering deep learning in structure-based drug discovery with its proprietary AtomNet® technology.
With over 600 unique disease targets and collaborations with more than 250 global partners, Atomwise has successfully cemented its role as a powerhouse in the AI-driven healthcare space, tackling formidable "undruggable" targets. Recent strategic expansions, such as the formation of a Scientific Advisory Board, highlight Atomwise's commitment to strengthening its internal pipeline.
To date, the company has secured over $174 million in venture capital funding. Its most recent investment was a $2.30M grant from the Bill & Melinda Gates Foundation in 2020, underscoring continued confidence in its innovative approach.
